Mesenchymal stem cells (MSCs) can differentiate into multiple cell lineages and are used for regenerative treatments for a variety of diseases. However, the patient's cells cannot be used to treat genetic diseases. Allogeneic cells can serve as an alternative but long-term survival is uncertain. Our experience of allo-transplantation to a patient with hypophosphatasia, which is caused by mutations of the tissue non-specific alkaline phosphatase (TNSALP) gene resulting in low serum alkaline phosphatase (ALP) activity and skeletal deformity, did not improve these clinical characteristics. Therefore, we sought to use autologous MSCs for the treatment of hypophosphatasia. MSCs derived from the patient's bone marrow had a similar profile when compared with well-reported MSCs. However, the MSCs had extremely low ALP activity and could not produce a mineralized bone matrix even under the osteogenic culture conditions. We therefore transduced a retroviral vector with TNSALP promoter-driven TNSALP gene in the MSCs. In the culture condition, the MSCs had about 7-fold higher ALP activity than did mock-transduced MSCs, and showed mineralization as well as bone-specific markers. Furthermore, the MSCs, but not mock-transduced MSCs, newly formed bone at the frequency of 50% in nude rats. Transplantation of the TNSALP-transduced autologous MSCs might become a new therapy for hypophosphatasia.
Introduction
Hypophosphatasia is a genetic disorder characterized by impaired bone mineralization and extremely low alkaline phosphatase (ALP) activity in serum and bone. The disease is caused by mutations in the tissue non-specific alkaline phosphatase gene (TNSALP). 1 The activity of ALP in serum and TNSALP genotype were reported to correlate with clinical forms of the disease. 2, 3 Depending on the age of onset and clinical symptoms, five clinical forms are categorized: perinatal, infantile, childhood, adult and odont forms. Almost all infants with severe forms of the disease (perinatal form) die in utero or shortly after birth and the disease has no established therapies. Various therapies such as cortisone, plasma and enzyme (ALP) replacement therapy have been attempted, but the results were inconsistent and did not lead to significant clinical improvement. The first trial of cell transplantation therapy for the disease was reported that an 8-month-old girl with infantile hypophosphatasia underwent bone marrow transplantation (BMT) using haplo-identical marrow from her healthy sister. 4 After 6 months from BMT, she further received culture expanded stromal cells from BM. The patient is alive as of the time the article was written. Mesenchymal stem cells ((MSCs), also referred to as mesenchymal stromal cells) are multipotent and can differentiate into not only mesenchymal lineages but also ectodermal and endodermal lineages. 5 These cells have been identified in several tissues such as bone marrow, 6 adipose tissue, 7 synovial tissue 8 and dental papilla tissue. 9 MSCs are thought to be an effective tool for regenerative medicine. 10 We have used human MSCs from the patient's bone marrow for treating various diseases centering on bone diseases since 2001. [11] [12] [13] MSCs and/or osteoblasts differentiated from MSCs have been transplanted into more than 80 patients.
In hypophosphatasia, we applied MSC transplantation therapy to a female infant with the disease.
14 The 8-month-old patient with perinatal hypophosphatasia received a BMT using fresh marrow from her father (HLA typing 3/6 matches) after immunosuppressive treatments. At 15 days post-BMT, MSCs and osteoblasts from her father were implanted. Furthermore, the patient received a booster shot of culture expanded MSCs when she was 16 months old. The patient's clinical symptoms improved after these treatments. In addition, implanted MSCs seemed to engraft and contribute to bone formation, because specific DNA sequence on the Y chromosome was detected in small samples of the patient's skull fragments. However, the biochemical parameters of ALP and skeletal deformity did not improve.
Our clinical experience of the allo-transplantation showed some degree of therapeutic effects, but these effects were limited and our recent report showed the simple implantation of allogeneic MSCs in rat model resulted in their rejection. 15 Therefore, we sought to use autologous (patient's own) MSCs for the treatment of hypophosphatasia, of which the main symptom is skeletal abnormality due to impaired mineralization of bone-forming osteoblasts. Owing to the genetic disorder of hypophosphatasia, introduction of normal gene into the patient's MSCs is required for therapeutic approach. In this regard, some used MSCs for the target of gene transduction and reported the production of important gene products. [16] [17] [18] However, there have been no reports of alkaline phosphatase gene transduction into the MSCs. Here, we report the restoration of the mineralization capability of normal TNSALP gene transduced hypophosphatasia patient MSCs in response to osteogenic differentiation.
Results

Characteristics of a female patient with hypophosphatasia
A radiograph of the patient at the age of 6 months showed deformed and poorly mineralized long bone ( Figure 1 ). DNA sequence analysis of the TNSALP gene detected a compound heterozygote: a missense mutation R433C (c.1348C4T point mutation) and a frameshift downstream from L503 (c.1559T deletion) derived from the patient's father and mother, respectively.
14 It has been reported that these ALP with the mutations are severe phenotypes. 19, 20 Characteristics of cells from a patient's bone marrow
The cultured cells from the patient's bone marrow showed small, spindle-shaped morphology ( Figure 2a ) and had high proliferative activity. Figure 2b ). We therefore concluded that these cells were MSCs. The ALP activity of the patient's MSCs was extremely low (Figure 3a) in spite of the expression of ALP molecules on the cell surface ( Figure 2b ). The MSCs did not produce a mineralized extracellular matrix even under osteogenic culture conditions (Figure 3b ). In contrast, the patient's father's MSCs with heterozygous mutation responded well to the culture conditions; the ALP activity of the father's MSCs were comparable with that of normal MSCs (without gene mutation) (Figure 3a ) and the MSCs showed mineralized matrix formation (Figure 3b ).
Chondrogenic and adipogenic differentiation capability in vitro
To assess their chondrogenesis potential, the patient's MSCs were cultured by a pellet culture system. The cell pellet increased its size during the culture period in the chondrogenic differentiation medium (Supplementary Figure 2A) . RT-PCR analysis revealed that the pellet expressed cartilage-specific extracellular matrix protein, type II collagen and aggrecan (Supplementary Figure 2B) . Cartilage matrix stainable with toluidine blue was clearly found in the pellet (Supplementary Figure 2C) . Furthermore, the cells could differentiate into adipocyte in adipogenic condition. The differentiation was confirmed by the appearance of adipocytes (Supplementary Figure 3A) and adipogenic marker expressions (Supplementary Figure 3B) .
Expression of normal ALP in the MSCs
As the patient MSCs showed neither high ALP activity nor mineralization, probably because of TNSALP gene mutation, we first transfected the plasmid DNA having normal TNSALP sequence into the MSCs (Supplementary Figure 1A ). The forced expression study of the transfected TNSALP gene with CMV promoter revealed that three transfected clones caused cell death in osteogenic culture condition ( Figure 4 ). We speculated that the overexpression of ALP under CMV promoter resulted in cell death, therefore we transfected the TNSALP gene with intrinsic TNSALP promoter into the MSCs. We found total 33 ALP-expressing clones, in which 27 clones showed good proliferation and produced mineralized extracellular matrix under the osteogenic condition (Figure 4 ). Though all MSCs with CMV promoter caused cell death, none of MSCs with TNSALP promoter caused cell death under the osteogenic condition. However, these cells did not show in vivo osteogenic differentiation (data not shown). Therefore, it was thought that the plasmid-transfected MSCs cannot be used in an in vivo situation. The cause of the failure of in vivo differentiation is not certain but the transfection efficiency might affect the differentiation capability.
Owing to the problem of the plasmid transfection, we used a more efficient vector of the retrovirus for further experiments and inserted the TNSALP gene with TNSALP promoter for regulation of the expression (Supplementary Figure 1B) . The cell shapes of the TNSALP-transduced MSCs were similar to those of mock-transduced MSCs (Figure 5a ) and non-transduced cells; all exhibited a fibroblastic cell shape. Retroviral transduction did not influence the expression of endogenous TNSALP mRNA and only TNSALP-transduced MSCs showed the transgene expression (Figure 5b ). Flow cytometric analysis showed that the patterns of forward and side scatter of these TNSALP-and mock-transduced MSCs were similar and thus, the morphological characteristics of these MSCs were the same (Figure 5c ). Furthermore, the panels of CD antigen expression were Figure 4) . However, the cell surface expression of ALP molecules was strongly enhanced in the TNSALP-transduced MSCs (Figure 5c ). Expression of ALP molecules was detected in all three separate experiments.
Osteogenic differentiation capability in vitro
To investigate in vitro osteogenic differentiation capability, TNSALP-transduced MSCs were cultured under osteogenic culture conditions for 4 weeks. The MSCs showed many ALP-stainable cells and fabricated mineralized extracellular matrices as seen in calcium stain using alizarin red S (Figure 6a ). In contrast, mocktransduced MSCs showed neither the ALP-stainable cells nor the mineralized matrix formation.
Biochemical analysis confirmed that the TNSALPtransduced MSCs had about 7-fold higher ALP activity than did the mock-transduced MSCs (Figure 6b ). To evaluate the mineralization, amount of calcium, which was deposited in extracellular matrix, was measured by o-cresolphthalein complexion method. And further, osteocalcin, which was deposited in mineralized matrix, was measured by enzyme-linked immunosorbent assay. Calcium and bone-specific osteocalcin were only detected in TNSALP-transduced MSCs (Figure 6b ).
To further analyze the osteogenic differentiation, expressions of other bone-related genes were investigated by RT-PCR analyses. As seen in Figure 6c , expressions of osteopontin, bone sialoprotein, osteocalcin, Matrix Gla protein were increased in TNSALPtransduced MSCs under osteogenic culture conditions. Mock-transduced MSCs also showed similar expression patterns.
In vivo bone formation
For the purpose of evaluation of bone formation in vivo, we combined the TNSALP-transduced MSCs to porous hydroxyapatite (HA) disks, and implanted them in nude rats for 6 weeks. Histological section of the retrieved MSCs/HA composites showed new bone formation in two out of four composites (Figure 7a ). In contrast, bone formation was not detected in all of four mocktransduced MSCs/HA composites and four control HA. Therefore, only TNSALP-transduced MSCs contributed to the new bone formation. To confirm the origin of the newly formed bone, the bone areas of the sections were cut with laser-assisted microdissection and used for PCR analysis. The analysis showed the existence of transgene and human gene in the dissected samples ( Figure 7b) . Accordingly, the TNSALP-transduced MSCs were able to survive even at subcutaneous sites in nude rats for at least 6 weeks and differentiate into bone-forming osteoblasts resulted in new bone formation. 
Discussion
Bone marrow contains not only hematopoietic stem cells but also mesenchymal stem cells, the source of osteoblasts. Therefore, bone marrow transplantation has been undertaken in patients with genetic bone diseases, for example osteogenesis imperfecta and may have a therapeutic effect in osteogenesis imperfecta. 21, 22 In hypophosphatasia, allogeneic bone marrow and/or MSC transplantation therapy has been reported by us and other groups. 4, 14, 23 However, the disease was not curable with these allo-transplantation therapies. In addition to the possible immunological rejection, allotransplantation is associated with some problems, such as infection and lack of appropriate donors. As a result, transplantation therapy might be suitable for treatments of genetic diseases by using genetically modified patient's own cells. The concept for a curative approach using gene manipulated MSCs for genetic diseases was postulated by Caplan AI in 1995 24 and recent reports evidenced the restoration of osteogenic function of human MSCs after gene transduction of bone morphogenetic protein 17 and type I collagen. 18 These facts encouraged us to transduce normal TNSALP gene into patient's MSCs, which showed excellent in vitro as well as in vivo mineralization (bone formation).
The MSCs derived from our patient's BM had similar profile compared with well-reported mesenchymal stem cells in view points of cell morphology and immunophenotype. In addition, the MSCs could differentiate into chondrocyte and adipocyte, and are thought to be multipotent cells. DNA sequence analysis revealed that the patient has a heterozygous mutation in TNSALP gene: 1348CoT (R433C) and 1559delT.
14 It was reported that ALP protein with 1559delT mutation locates in cytoplasm 25 but the protein with R433C mutation appears to localize on the cellular membrane. 26 As we could detect the cell surface expression of ALP by flow cytometric analysis, cascades of transcription followed by translation of the TNSALP gene and transportation of translational product to cellular membrane well occurred in the patient's cell. However, we could hardly detect ALP activity of the MSCs. In this regard, it has been reported that the ALP with these mutations has only 0-5% activity compared with wild-type ALP 26, 27 It is well known that mineralization by osteoblasts requires high ALP activity and our findings of patient MSC with little ALP activity hardly showed the mineralization. Osteoblasts derived from TNSALP knockout mice also lacked the mineralization ability. 28 Interestingly, the expression of other bone-related genes such as osteocalcin and ALP gene transduction into the patient's MSC Y Katsube et al osteopontin were found in osteoblasts in the TNSALP knockout mice, thus osteogenic differentiation could occur in the mice but lacked the mineralization capability. Similarly, our patient's MSCs expressed these bone-related genes in the osteogenic culture, although they hardly showed mineralization. The mineralization as well as normal ALP activity could be detected after transduction of normal TNSALP gene.
Concerning the gene expression of TNSALP, it is thought that the level of ALP activity should be appropriately regulated, because excessive expression of ALP causes cell death in osteogenic culture condition. Therefore, we transduced the gene under TNSALP promoter into MSCs that showed in vitro mineralization in the culture condition as well as in vivo new bone formation after their transplantation in athymic nude rats. Therefore, a patient's own MSCs instead of allogeneic MSCs can be used for transplantation therapy and might contribute to facilitate bone mineralization in the hypophosphatasia patients.
One drawback of our approach is the usage of retroviral vector, which integrates randomly into host genome and may increase the risk of cancer. 29 However, the risk may be circumvented if we identify the integration sites. Another approach without using retroviral vector is gene targeting, 30 which needs extensive proliferative cellular activity, but the activities of adult stem cells such as MSCs are not enough to use for medical treatments and this approach remains difficult. Recently, systems for site-specific DNA integration in human cells are developed. For example, adeno-associated virus vector can integrate at a site on human chromosome 19 termed AAVS1 by Rep protein 31 and the system may be available without risks of cancer. In 
ALP gene transduction into the patient's MSC
Y Katsube et al future, recently generated induced pluripotent stem cells 32 will be available instead of the MSCs, because the induced pluripotent stem cells can theoretically differentiate into all kinds of tissue-specific cells including osteoblasts. Furthermore, mutated genes in the patient-derived induced pluripotent stem cells can be converted into normal genes by homologous recombination. Thus, we can use patient induced pluripotent stem cells having normal gene for the treatment, however, we must overcome many problems such as tumor (teratoma) formation and risk of cancer because of the usage of plural vectors, which might integrate into a host genome.
MSCs from a hypophosphatasia patient restored mineralization capability by transducing the normal TNSALP gene. Cell transplantation therapy using the MSCs is an attractive candidate for clinical treatment of hypophosphatasia. Furthermore, because of the multidifferentiation capability of MSCs, our strategy using genetically modified autologous MSCs may also be effective for treating other types of genetic diseases. Further studies are required to elucidate the efficacy of normal gene transduction into MSCs for the purpose of clinical applications.
Materials and methods
Culture of MSCs
After informed consent from parents and the permission of the local ethics committees of both AIST and the Shimane University Faculty of Medicine were obtained, about 1 ml of fresh bone marrow was harvested from the patient at the age of 8 months and mixed with an equal volume of heparinized phosphate-buffered saline. The whole bone marrow was seeded in a 100 mm cell culture dish with basal medium consisting of minimum essential medium alpha (a-MEM, Life Technologies Corp., Carlsbad, CA, USA) containing 15% fetal bovine serum (Life Technologies Corp.) and antibiotics. The culture was done in a humidified atmosphere of 95% air with 5% CO 2 at 37 1C; the culture medium was changed two or three times a week. After 2 weeks of culture, adherent cells were harvested, suspended in the Cell Banker (Juji Field, Tokyo, Japan) and cryopreserved in liquid nitrogen before use. MSCs derived from her father and a healthy donor were prepared as previously described. 11 In this study, cryopreserved cells were thawed and recultured in basal medium. Cells were used at passage 2 for plasmid transfection and retroviral transduction.
Plasmid transfection
The DNA fragment containing the entire open reading frame of TNSALP was isolated by PCR from human cDNA clone, FCC155F10 (Toyobo Co., Ltd, Osaka, Japan). The EGFP fragment of pEGFP-N1 vector (Clontech Laboratories Inc., Mountain View, CA, USA) was replaced with the TNSALP fragment to make the TNSALP-forced expression vector ( Supplementary Figure 1A) . To regulate TNSALP expression by a TNSALP promoter, the CMV promoter of the TNSALP-forced expression vector was replaced with the 5 0 -flanking region of the TNSALP gene, which was excised with Sac I and Fsp I from a human BAC clone, RP11-293F5 (BACPAC Resources, Children's Hospital Oakland, Oakland, CA, USA). It has been reported that the region has promoter activity in osteogenic cells. 33 pEGFP-N1 vector was used as a mock vector. These plasmids were transfected into the MSCs by using HilyMax transfection reagent (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer's instructions. These cells were selected in G418 (Merck KGaA, Darmstadt, Germany) (200 mg ml -1 ), and several clones were obtained. 
Retroviral transduction
Retroviral transduction of the TNSALP gene was done by using Retro-X Q Vector, pQCXIN (Clontech Laboratories Inc.) (Supplementary Figure 1B) . The TNSALP expression cassette containing the TNSALP promoter was subcloned into pQCXIN. The plasmids with or without a TNSALP promoter-driven normal TNSALP gene were transfected into retroviral-producing cells, PT67 (Clontech Laboratories Inc.), by using HilyMax transfection reagent. The PT67 cells were cultured in the presence of G418 (400 mg ml -1 ) and passaged several times. For infection of the MSCs, the PT67 cells were cultured in a basal medium without G418 for 2 days. The viruscontaining supernatants derived from the PT67 cells were filtered and added with polybrene (Millipore Corporation, Billerica, MA, USA) (8 mg ml -1 ). MSCs were incubated overnight in the supernatants. Infection experiments were done twice with an interval of 1 day. After the second infection, we added G418 (200 mg ml -1 ) for selection. The MSCs were passaged once before the following analyses.
RT-PCR
Total RNA from cultured cells was isolated by TRIzol Reagent (Life Technologies Corp.). The total RNA was reverse-transcribed using ReverTra Ace (Toyobo Co., Ltd.) in 20 ml reaction volume. The PCR mixture (20 ml) contained 0.1 ml Ex Taq HS (Takara Bio Inc., Shiga, Japan), 2 ml 10 Â buffer, 1.6 ml dNTPs mixture, 0.2 mM concentration of appropriate primer, 2 ml cDNA and RNase-free water. PCRs were performed using the 
Flow cytometric analysis
To characterize the expression of cell surface antigens, the MSCs were incubated with FITC-conjugated CD antibodies on ice for 30 min. They were then washed and passed through cell strainers (Becton Dickinson and Company (BD), Franklin Lakes, NJ, USA) to remove any cell clumps. Flow cytometric analysis was performed on a FACS Calibur system (BD). The following mouse antihuman monoclonal antibodies were used: FITC-conjugated CD13 (TÜ K 1), CD14 (Tü k 4), CD44 (MEM85), CD45 (HI30) (BioCarta Inc., San Diego, CA, USA), CD34 (581), HLA class I (Tu149) (Life Technologies Corp.), CD29 (4B7R), CD90 (F15-42-1), CD105 (SN6), CD166 (3A6) (AbD Serotec, Raleigh, NC, USA) and PE-conjugated CD73 (AD2) (BD). FITC and PE-conjugated mouse IgG (Beckman Coulter Inc., Fullerton, CA, USA) were used as negative controls. For analysis of cell surface ALP expression, mouse anti-human ALP monoclonal antibody (B4-78; purified in our laboratory) was used. After a washing step, FITC-conjugated goat anti mouse IgG antibody (Leinco Technologies Inc., St. Louis, MO, USA) was subsequently reacted.
In vitro osteogenic differentiation
MSCs were seeded at a density of 5 Â 10 3 cells per cm 2 in a 24-well culture plate in basal culture medium and cultured overnight. The medium was changed the next day to osteogenic differentiation medium, which was supplemented with 10 mM b-glycerophosphate (Merck KGaA), 0.07 mM L-ascorbic acid 2-phosphate magnesium salt n-hydrate (Wako Pure Chemical Industries Ltd., Osaka, Japan) and 100 nM dexamethasone (SigmaAldrich, St Louis, MO, USA). The medium was changed twice a week. The MSCs were also cultured in control medium, which was supplemented only with 10 mM b-glycerophosphate.
Analyses of biochemical properties after osteogenic differentiation
For measurement of DNA content and ALP activity after the osteogenic differentiation, the cells were washed with phosphate-buffered saline and collected by scraping into a tube containing 500 ml of 10 mM Tris buffer (pH 7.4, 1 mM EDTA and 100 mM NaCl). The sample was sonicated, after which 20 ml of the sonicated cell suspension was used to quantify the DNA content by using Hoechst 33258. Standard DNA was prepared with salmon sperm DNA (Life Technologies Corp.). The sonicated cell suspension was centrifuged at 13 000 g for 5 min at 4 1C, and 20 ml of the supernatant was used for ALP activity measurement. p-Nitrophenylphosphate (pNPP) (Zymed Laboratories Inc., South San Francisco, CA, USA) was used as the substrate, and the pnitrophenol released during incubation for 30 min at 37 1C was measured as ALP activity. The ALP activity was normalized to DNA content (mmol mg -1 ). For measurement of calcium in the mineralized matrices, the sonicated cell suspension was added with equal amounts of 20% formic acid. After several days, the sample was centrifuged at 13 000 g for 5 min at 4 1C, and the supernatant was used. Calcium concentration was measured by using Wako Calcium C (Wako Pure Chemical Industries Ltd.) according to the manufacturer's instructions.
For measurement of osteocalcin in the mineralized matrices, 500 ml of the supernatant of formic acid-added sample was loaded onto the gel filtration column, NAP-5 (GE Healthcare UK Ltd., Buckinghamshire, England) for the purpose of eliminating inorganic ions. The eluted sample was desiccated and suspended in 500 ml of the sample buffer of Intact Human Osteocalcin EIA Kit (Biomedical Technologies Inc., Stoughton, MA, USA). The osteocalcin concentration was measured by using the kit according to the manufacturer's instructions.
Visualization of the mineralized extracellular matrix by alizarin red S staining
Alizarin red S staining was used to detect the mineralized extracellular matrix of the osteogenic differentiation cultured cells. The cells were washed and fixed with 10% paraformaldehyde for 10 min at RT. The fixed cells were stained with 0.1% alizarin red S solution (Wako Pure Chemical Industries Ltd.) for 10 min and washed to remove the remaining stain.
Visualization of the ALP expression by ALP staining
To visualize ALP expression, the cells were washed and fixed with 10% paraformaldehyde for 10 min at RT. The fixed cells were incubated in 0.05% naphthol AS-MX phosphate (Nacalai Tesque Inc., Kyoto, Japan) and 0.05% fast red violet LB salt (Nacalai Tesque Inc.) in 56 mM ALP gene transduction into the patient's MSC Y Katsube et al 2-amino-2 methyl-1, 3-propanediol (pH 9.9) for 10 min at RT and washed to remove the remaining stain.
In vivo bone formation
To examine in vivo bone formation of MSCs, we used a previously reported transplantation model. 34 MSCs were suspended in basal culture medium at a density of 5 Â 10 6 cells per ml. HA disks (5 mm in diameter and 2 mm thick, Cellyard, HOYA Corporation, Tokyo, Japan) were soaked in the suspension and incubated overnight. The MSC/HA composites were implanted into immunocompromised rats for evaluation of in vivo bone formation. Nude rats (7-week-old male F344/N Jcl-rnu/ rnu rats) were purchased from CLEA Japan Inc. (Tokyo, Japan). The rats were anesthetized with pentobarbital (50 mg kg -1 i.p.) and the MSC/HA were implanted subcutaneously into their backs. HA disks only were similarly implanted as negative control. After 6 weeks, the implants were harvested, fixed in 10% buffered formalin, and decalcified with 10% EDTA/phosphatebuffered saline solution. They were embedded in paraffin, sectioned and stained with hematoxylin and eosin. The histological section showing the osteoblasts lining on extracellular matrix (bone matrix) together with osteocytes in lacunae was considered as positive bone formation. The animal experiment was approved by the animal care and use committee of AIST.
To determine the origin of newly formed bone, the bone areas having osteocytes in the histological specimens were cut with laser-assisted microdissection (LMD) system (Leica Microsystems GmbH, Wetzlar, Germany) and used for isolation of the genomic DNA with a QIAamp DNA Micro Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. Nested PCR was used to detect the DNA with human origin. Twenty-five cycles of first PCR were performed as RT-PCR, as described above. The amplicons of first PCR were diluted 10-fold and amplified again by 25 cycles of second PCR. The following primers were used (forward and reverse, 5 0 -3 0 ): Human TNSALP (transgene): 1st PCR GGACCCAGGAAACCAAAGTC and ACCG TAAGTTATGTAACGGACTCTA 2nd PCR CTTTGGCCACCAGGGTAGAT and ACCG TAAGTTATGTAACGGACTCTA Human b-globin (HBB): 1st PCR CAACTTCATCCACGTTCACC and AGCAA CCTCAAACAGACACCATGG (UniSTS: 273688) 2nd PCR CTTCATCCACGTTCACCTTG and CATGG TGCATCTGACTCCTG
In vitro chondrogenic differentiation
MSCs were cultured by using hMSC Differentiation BulletKit, Chondrogenic (Lonza Walkersville Inc., Walkersville, MD, USA) according to the manufacturer's instructions with slight modifications. In brief, 2.5 Â 10 5 cells were suspended in 500 ml of complete chondrogenic differentiation medium containing 10 ng ml -1 of TGF-b3 (R&D Systems Inc., Minneapolis, MN, USA) and 500 ng ml -1 of BMP2 (R&D Systems Inc.). The cell suspension was placed in a polypropylene tube and centrifuged at 150 g for 5 min. The tube was incubated in a humidified atmosphere of 95% air with 5% CO 2 at 37 1C. The medium was changed every 2-3 days. The MSCs were also cultured in incomplete chondrogenic differentiation medium without TGF-b3 and BMP2. After 3 weeks, cell pellets were fixed with 10% paraformaldehyde. These samples were embedded in paraffin, sectioned and stained with toluidine blue.
In vitro adipogenic differentiation
MSCs were cultured by using hMSC Differentiation BulletKit, Adipogenic (Lonza Walkersville Inc.) according to the manufacturer's instructions. After 3 weeks of adipogenic culture, the cells were washed and fixed with 10% paraformaldehyde for 10 min at RT. The fixed cells were washed with 60% isopropanol and stained with oil red O solution for 20 min. The stained cells were then washed with isopropanol and phosphate-buffered saline to remove the remaining stain.
Statistical analysis
Values are expressed as averages and s.d. Student's t-test was used for statistical analysis. P-values less than 0.01 were considered statistically significant.
